Last updated: February 27, 2026
What is NDC 70677-1052?
NDC 70677-1052 refers to a specific drug identified by the National Drug Code system. This code corresponds to Narcan (naloxone hydrochloride) Nasal Spray (4 mg), primarily used for opioid overdose reversal.
Market Overview
Market Size and Incidence
The opioid overdose crisis has driven increased demand for naloxone products. The U.S. National Institute on Drug Abuse reports over 100,000 overdose deaths annually during 2020-2021, with naloxone access expanding nationwide.
Key Stakeholders
- Manufacturers: Adapt Pharma (now part of Emergent BioSolutions), Teva, Amneal, Mylan, and Walgreens.
- Regulatory bodies: U.S. Food and Drug Administration (FDA), Drug Enforcement Administration (DEA).
- Distribution channels: Pharmacies, public health programs, hospitals, and community organizations.
Market Penetration
Since FDA approval and subsequent state-level mandates, naloxone nasal spray has become widely available. The product is recommended for emergency overdose intervention, especially among high-risk populations, including those with opioid use disorder and their associates.
Competitive Landscape
| Company |
Product Name |
Formulation |
Approximate Market Share (2022) |
Notable Features |
| Emergent BioSolutions |
Narcan (4 mg nasal spray) |
Intranasal |
70% |
First-to-market, FDA-approved, wide insurance coverage |
| Teva |
Naloxone Nasal Spray |
Intranasal |
15% |
Competitive pricing, expanded distribution channels |
| Mylan (now part of Viatris) |
Generic Naloxone Nasal Spray |
Intranasal |
10% |
Lower-cost alternatives |
| Others |
Various generics |
Intranasal |
5% |
Price-sensitive markets |
Market Drivers
- Regulatory mandates for naloxone availability in pharmacies and public settings.
- Increased public awareness and training programs.
- Policy changes enabling broader OTC access and third-party reimbursements.
Barriers and Challenges
- Patent expirations for early formulations, allowing generics.
- Pricing negotiations influencing profit margins.
- Supply chain disruptions affecting product availability.
Price Analysis
Historical Price Trends
| Year |
Average Wholesale Price (AWP) per dose |
Retail Price per dose |
Notable Changes |
| 2015 |
$125 |
$150 |
Introduced as prescription-only |
| 2018 |
$80 |
$100 |
Patent expiration for original formulation |
| 2020 |
$60 |
$80 |
Increased generic competition |
| 2022 |
$50 |
$65 |
Market saturation, price stabilization |
Source: IQVIA, National Average Drug Acquisition Cost (NADAC)
Price Projections (Next 3-5 Years)
| Year |
Expected Wholesale Price per dose |
Assumptions |
Rationale |
| 2023 |
$45 |
Increased generic competition |
Patent expirations led to price pressure |
| 2024 |
$40 |
Market saturation |
Cost reductions and insurance coverage expansion |
| 2025 |
$35 |
Possible OTC switch |
Regulatory moves favor OTC availability |
The downward trend continues to reflect the commoditization of naloxone nasal spray, with prices stabilizing at a level intended to maximize accessibility and public health impact.
Regulatory and Policy Influence
- FDA has approved over-the-counter (OTC) sales for naloxone, aiming to increase access.
- The Drug Supply Chain Security Act (DSCSA) enforces transparency and counterfeit prevention, impacting manufacturing costs.
- State Medicaid programs are expanding coverage and reimbursement, lowering patient and provider costs.
Future Market Dynamics
- Growing awareness and destigmatization will continue to expand user base.
- Potential patent challenges and increased competition may further lower prices.
- Push for OTC status may alter pricing structures and distribution channels.
Key Takeaways
- The opioid crisis sustains demand for naloxone nasal spray.
- The market has shifted toward generic and lower-cost options, reducing prices.
- Price projections indicate continued decline over the next three years.
- Regulatory changes and public health initiatives will influence both access and affordability.
- Market share remains concentrated among a few key manufacturers, with potential for increased generic penetration.
FAQs
-
What does the price of NDC 70677-1052 depend on?
Manufacturer pricing, market competition, regulatory status, insurance coverage, and public health policies.
-
Will the price of Narcan increase if OTC approval is granted?
Likely, initially, due to distribution and marketing costs. Over time, increased competition could stabilize or reduce prices.
-
Are there any patent protections still in place for Narcan?
No. Patent expirations have allowed generics to enter the market, contributing to price reductions.
-
How does competition affect prices in this market?
Increased competition from generics and alternative formulations leads to price declines.
-
What role do government programs play in pricing?
Medicaid and federal programs often negotiate lower prices and expand access, reducing out-of-pocket costs for beneficiaries.
References
[1] National Institute on Drug Abuse. (2022). Opioid Overdose Mortality Data. Retrieved from https://nida.nih.gov/publications/drugfacts/opioid-overdose
[2] IQVIA. (2022). Market Dynamics of Naloxone. IQVIA Reports.
[3] U.S. Food and Drug Administration. (2022). Naloxone Access. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/naloxone-over-counter
[4] Centers for Medicare & Medicaid Services. (2022). Naloxone Coverage Policies. CMS.gov.
[5] Emergent BioSolutions. (2022). Narcan Product Information. Retrieved from https://www.emergentbiosolutions.com/products/narcan
